InvestmentOpportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries. Cabinet Approves Promotion ofDomestic Manufacturing of Critical Key Starting Materials-Drug Intermediatesand Active Pharmaceutical Ingredients in the Country.
Key Starting Materials (KSMs)/Drug Intermediates
KSMsfrom the essentialmedicines list for strategic reasons posed by the COVID-19.
Role of Government towards(KSMs)/Drug Intermediates
TheUnion Cabinet chaired by the Prime Minister, Shri Narendra Modi has approvedthe following schemes:
Thescheme on Promotion of BulkDrugParks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks withfinancial implication of Rs. 3,000 crore for next five years.
ProductionLinked Incentive (PLI) Scheme for promotion of domestic manufacturing ofcritical KSMs/DrugIntermediates and APIs in the country with financialimplications of Rs6, 940 crore for next eight years.
